2. Search Result
Search Result
Results for "

synovial+sarcoma

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145925B
    CFT8634
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    CFT8634 is an orally bioavailable PROTAC BRD9 targeted degrader based on the E3 ubiquitin ligase CRBN mechanism. CFT8634 can be used for the study of synovial sarcoma and SMARCB1-deficient solid tumors (Pink: BRD9 ligand (HY-169988); Blue: E3 ligase ligand (HY-169989); Black: linker (HY-169991). CFT8634 is a heterobifunctional molecule that binds to BRD9 at one end and recruits CRBN at the other end, which can inhibit the growth of tumor cells that depend on BRD9. CFT8634 can be used for the study of SMARCB1-related cancers (such as synovial sarcoma and malignant rhabdoid tumor) .
    CFT8634
  • HY-159579
    CW-3308

    		PROTACs Epigenetic Reader Domain Cancer
    CW-3308 is an orally active BRD9 PROTAC degrader with an DC50 of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .
    CW-3308
  • HY-148739
    dBRD 9-A

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
    dBRD 9-A
  • HY-P99581
    Tabituximab barzuxetan (exclude Y90)

    OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
    Tabituximab barzuxetan (exclude Y90)
  • HY-178345
    ZZ7-23-022

    ZZ7

    		 Molecular Glues Epigenetic Reader Domain Cancer
    ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer .
    ZZ7-23-022
  • HY-N16372
    Pronqodine A

    		Indoleamine 2,3-Dioxygenase (IDO) Quinone Reductase Reactive Oxygen Species (ROS) Inflammation/Immunology
    Pronqodine A is an Indoleamine 2,3-Dioxygenase (IDO) inhibitor, with an IC50 of 131.5 nM. Pronqodine A inhibits bradykinin-induced release of PGE2, 6-keto-prostaglandin F1α, PGD2 and induces the production of reactive oxygen species (ROS) in human synovial sarcoma SW982 cells. Pronqodine A is a good substrate for human quinone reductase NQO1. Pronqodine A can be used for the study of inflammation .
    Pronqodine A
  • HY-182082
    XYD270

    		PROTACs Epigenetic Reader Domain Cancer
    XYD270 is an orally active BRD9 PROTAC degrader. XYD270 inhibits the proliferation of cancer cells. XYD270 suppresses tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .
    XYD270
  • HY-182084
    BRD9 ligand-12

    		Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    BRD9 ligand-12 is a BRD9 ligand. BRD9 ligand-12 can be used as a ligand for target protein for PROTAC to develop and design degradative agents for PROTAC BRD9, such as XYD270 (HY-182082). XYD270 inhibits tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .
    BRD9 ligand-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: